drugset / Trial / NCT06501911

A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma

NCT06501911

Phase 1 Withdrawn University of Nebraska
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to learn about a type of brain cancer called high-grade glioma. This study is for people who have previously received treatment for brain cancer, but the cancer has come back or gotten worse after treatment. The main question this study aims to answer is: is it safe for participants to take bicalutamide while receiving brain radiation treatment? Participants will: * Take bicalutamide every day for 6 months * Receive radiation treatment to the brain * Keep a diary of the when they take the bicalutamide and any side effects experienced * Visit the clinic once every 8 weeks for checkups and tests

Timeline

Start
2025-04-08
Primary completion
2025-07-17
Completion
2025-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 25 mg Oral
Subject Bicalutamide Other / unclassified 150 mg Oral
Subject Bicalutamide Other / unclassified 600 mg Oral

Indications